Ellence (EPIRUBICIN HYDROCHLORIDE)
Ellence (EPIRUBICIN HYDROCHLORIDE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Ellence; Generic name: EPIRUBICIN HYDROCHLORIDE; Manufacturer: Pharmacia & Upjohn Company LLC.
| Brand name | Ellence |
|---|---|
| Generic name | EPIRUBICIN HYDROCHLORIDE |
| Manufacturer | Pharmacia & Upjohn Company LLC |
| Used for | 1 INDICATIONS AND USAGE ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1) ] . ELLENCE is an anthracycline topoisomerase inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer ( 1 ). |
| Dosage | 2 DOSAGE AND ADMINISTRATION • The recommended starting dose of ELLENCE is 100 to 120 mg/m 2 . Dosage reductions are possible when given in certain combinations ( 2.2 ). • Administer intravenously in repeated 3- to 4-week cycles, either total dose on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle ( 2.2 ). • Consider use of antiemetics when given in conjunction with other emetigenic drugs ( 2.1 ). • Patients administered the 120 mg/m 2 regimen of ELLENCE should rece |
| Warnings | WARNING: CARDIAC TOXICITY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION • Cardiac Toxicity: Myocardial damage, including acute left ventricular failure, can occur with ELLENCE. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 0.9% at a cumulative dose of 550 mg/m 2 , 1.6% at 700 mg/m 2 , and 3.3% at 900 mg/m 2 . The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left |
| Active ingredient(s) | EPIRUBICIN HYDROCHLORIDE |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a03c798-a652-4895-b29c-3b521a89ba42 |